(A) Spatial distribution of significant differences in scaling exponent α between Task-counting and Fixation during the Placebo (left), Atomoxetine (middle), and Donepezil condition (right). (B) Comparison between mean scaling exponents α averaged across the entire brain (see Materials and methods) during the different pharmacological conditions. (C) Individual subject differences in scaling exponent α between all drug conditions. (D, E) Spatial distribution of drug-induced changes in scaling exponents. (D) Atomoxetine versus placebo. (E) Donepezil versus placebo. Two-sided permutation tests (N = 28); all statistical maps: threshold at p = 0.05, cluster based. All drug comparisons are averaged across behavioral conditions, i.e., Fixation and Task-counting. The data can be found at https://figshare.com/articles/DFA_source_level_/5755311. MEG, magnetoencephalographic; n.s., not significant.